Latest & greatest articles for metformin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on metformin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on metformin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for metformin

181. Adjunctive metformin for antipsychotic-related hyperprolactinemia: a meta-analysis of randomized controlled trials

Adjunctive metformin for antipsychotic-related hyperprolactinemia: a meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2017 PROSPERO

182. Efficacy and safety of extended-release metformin vs. immediate-release metformin in patients with type 2 diabetes : a systematic review and meta-analysis

Efficacy and safety of extended-release metformin vs. immediate-release metformin in patients with type 2 diabetes : a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2017 PROSPERO

183. Metformin and lifestyle intervention for antipsychotic-related weight gain: a meta-analysis of randomized controlled trials

Metformin and lifestyle intervention for antipsychotic-related weight gain: a meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2017 PROSPERO

184. Co-administration of proton pump inhibitors and metformin: a systematic review

Co-administration of proton pump inhibitors and metformin: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2017 PROSPERO

185. The effect of adding metformin to insulin therapy for children with type 1 diabetes mellitus: a systematic review protocol

The effect of adding metformin to insulin therapy for children with type 1 diabetes mellitus: a systematic review protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2017 PROSPERO

186. Metformin decreases progerin expression and alleviates pathological defects of Hutchinson–Gilford progeria syndrome cells Full Text available with Trip Pro

Metformin decreases progerin expression and alleviates pathological defects of Hutchinson–Gilford progeria syndrome cells Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disorder that causes systemic accelerated aging in children. This syndrome is due to a mutation in the LMNA gene that leads to the production of a truncated and toxic form of lamin A called progerin. Because the balance between the A-type lamins is controlled by the RNA-binding protein SRSF1, we have (...) hypothesized that its inhibition may have therapeutic effects for HGPS. For this purpose, we evaluated the antidiabetic drug metformin and demonstrated that 48 h treatment with 5 mmol/l metformin decreases SRSF1 and progerin expression in mesenchymal stem cells derived from HGPS induced pluripotent stem cells (HGPS MSCs). The effect of metformin on progerin was then confirmed in several in vitro models of HGPS, i.e., human primary HGPS fibroblasts, LmnaG609G/G609G mouse fibroblasts and healthy MSCs

2016 NPJ aging and mechanisms of disease

187. [Empagliflozin/metformin]

[Empagliflozin/metformin] Empagliflozin/metformin (diabetes mellitus Typ 2): addendum zum auftrag A16-13; auftrag A16-47 [Empagliflozin/metformin - addendum to commission A16-13] Empagliflozin/metformin (diabetes mellitus Typ 2): addendum zum auftrag A16-13; auftrag A16-47 [Empagliflozin/metformin - addendum to commission A16-13] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Empagliflozin/metformin (diabetes mellitus Typ 2): addendum zum auftrag A16-13; auftrag A16-47. [Empagliflozin/metformin - addendum to commission A16-13] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 418. 2016 Final publication URL Indexing Status Subject indexing

2016 Health Technology Assessment (HTA) Database.

188. Metformin Use in Patients with Historical Contraindications or Precautions

Metformin Use in Patients with Historical Contraindications or Precautions Management Briefs eBrief-no116 -- Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs eBrief-no116 -- Health Services Research & Development Management eBrief no. 116 » Issue 116 October 2016 The report is a product of the VA/HSR&D Evidence Synthesis Program. Metformin Use in Patients with Historical (...) Contraindications or Precautions Metformin is an oral hypoglycemic medication used primarily for treating type 2 diabetes mellitus. Evidence suggests that in addition to improving glycemic control, metformin may be associated with improved all-cause and cardiovascular mortality and decreased risk of some cancers. However, clinicians have traditionally been advised by the U.S. Food and Drug Administration (FDA) to exercise caution in prescribing metformin to individuals with chronic kidney disease (CKD

2016 Veterans Affairs - R&D

189. Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study) Full Text available with Trip Pro

Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study) Gemigliptin is a new dipeptidyl peptidase-IV inhibitor. We investigated the efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes (T2D).A total of 433 T2D patients (...) with a glycosylated haemoglobin (HbA1c) level of 7.5% to 11.0% and a fasting plasma glucose (FPG) concentration <270 mg/dL were randomly assigned to 3 groups: (1) gemigliptin 50 mg qd + metformin 1000 to 2000 mg qd (titrated individually), (2) gemigliptin 50 mg qd, or (3) metformin 1000 to 2000 mg qd. The primary end-point was the change in HbA1c level after 24 weeks. Secondary end-points were the changes in FPG, insulin, proinsulin and C-peptide levels. The percentages of responders who achieved an HbA1c level

2016 EvidenceUpdates

190. Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function

Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function | European Medicines Agency Search Search Menu Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function Press release 14/10/2016 Recommendations for patients with kidney impairment updated in The European Medicines Agency (EMA) has concluded that metformin (...) -containing medicines can now be used in patients with moderately reduced kidney function (GFR [glomerular filtration rate]=30–59 ml/min) for the treatment of type 2 diabetes. The for these medicines will be updated to revise the current contraindication and give information about doses, monitoring and precautions in patients with reduced kidney function. The recommendations are the result of a review by EMA of metformin-containing medicines following concerns that current scientific evidence does

2016 European Medicines Agency - EPARs

191. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Full Text available with Trip Pro

Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Metformin use has been associated with a reduced risk of developing cancer and an improvement in overall cancer survival rates in meta-analyses, but, to date, evidence to support the use of metformin as an adjuvant therapy in individual cancer types has not been presented.We systematically searched research databases, conference abstracts and trial registries for any studies reporting cancer outcomes (...) for individual tumour types in metformin users compared with non-users, and extracted data on patients with early-stage cancer. Studies were assessed for design and quality, and a meta-analysis was conducted to quantify the adjuvant effect of metformin on recurrence-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS), to inform future trial design.Of 7670 articles screened, 27 eligible studies were identified comprising 24 178 participants, all enrolled in observational studies

2016 Annals of oncology : official journal of the European Society for Medical Oncology

192. Effect of metformin treatment during pregnancy on women with PCOS: a systematic review and meta-analysis. (Abstract)

Effect of metformin treatment during pregnancy on women with PCOS: a systematic review and meta-analysis. Some previous studies have found that continued metformin use is beneficial in the management of polycystic ovary syndrome (PCOS) in pregnant women. A systemic review and meta-analysis were needed to more fully assess the effects of metformin on pregnant PCOS patients.The literature was fully searched using MEDLINE, EMBASE, SCOPUS, and COCHRANE for continued metformin use during pregnancy (...) in women with PCOS. A systematic review and meta-analysis were performed to evaluate the comprehensive effects of continued metformin treatment on pregnancy-related outcomes in these women.Eleven eligible studies out of 127 relevant publications were included in meta-analysis. The rates of early pregnancy loss and preterm delivery were found to be significantly decreased in metformin-treated PCOS women. A non-significant difference was found in fetal abnormality and fetal birth weight between

2016 Clinical and investigative medicine. Médecine clinique et experimentale

193. Does metformin reduce excess birthweight in offspring of obese pregnant women? A randomised controlled trial of efficacy, exploration of mechanisms and evaluation of other pregnancy complications Full Text available with Trip Pro

Does metformin reduce excess birthweight in offspring of obese pregnant women? A randomised controlled trial of efficacy, exploration of mechanisms and evaluation of other pregnancy complications Does metformin reduce excess birthweight in offspring of obese pregnant women? A randomised controlled trial of efficacy, exploration of mechanisms and evaluation of other pregnancy complications Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found (...) Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Metformin taken by obese pregnant women did not reduce their baby's birthweight. {{author}} {{($index , , , , , , , , , , , , , , , , , , , , , & . Carolyn A Chiswick 1 , Rebecca M Reynolds 2 , Fiona C Denison 1 , Amanda J

2016 NIHR HTA programme

194. Glucose Control in Severely Burned Patients Using Metformin: An Interim Safety and Efficacy Analysis of a Phase II Randomized Controlled Trial (Abstract)

Glucose Control in Severely Burned Patients Using Metformin: An Interim Safety and Efficacy Analysis of a Phase II Randomized Controlled Trial To determine whether metformin can achieve glucose control no worse than insulin (noninferiority) without the danger of hypoglycemia (superiority). In addition, to assess whether metformin has any additional effects on lipolysis and inflammation that will enhance burn recovery (superiority).Hyperglycemia and insulin resistance after burn injury (...) are associated with increased morbidity and mortality. Insulin administration improves postburn infections, severity of sepsis, and morbidity, but also causes a 4-5-fold increase in hypoglycemia, which is associated with a 9-fold increase in mortality.Severely burned adult patients with burns over 20% total body surface area (TBSA) burn were prospectively randomized in this Phase II clinical trial to either metformin or insulin (standard of care) treatment. Primary outcomes were glucose levels and incidence

2016 EvidenceUpdates Controlled trial quality: uncertain

195. [Empagliflozin/metformin: benefit assessment according to õ35a Social Code Book V]

[Empagliflozin/metformin: benefit assessment according to õ35a Social Code Book V] Empagliflozin/Metformin: nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A16-1 [Empagliflozin/metformin: benefit assessment according to §35a Social Code Book V] Empagliflozin/Metformin: nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A16-1 [Empagliflozin/metformin: benefit assessment according to §35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (...) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Empagliflozin/Metformin: nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A16-1. [Empagliflozin/metformin: benefit assessment according to §35a Social Code Book V] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit

2016 Health Technology Assessment (HTA) Database.

196. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register (Abstract)

Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register To investigate the relative safety of various glucose-lowering agents as add-on medication to metformin in type 2 diabetes in an observational study linking five national health registers.Patients with type 2 diabetes who had been on metformin monotherapy and started another agent in addition to metformin were eligible for inclusion (...) treatment was associated with significantly lower risks of CVD, fatal CVD, CHD, fatal CHD and CHF.This nationwide observational study showed that second-line treatment with TZD and DPP-4 inhibitor as add-on medication to metformin were associated with significantly lower risks of mortality and cardiovascular events compared with SU, whereas basal insulin was associated with a higher risk of mortality.© 2016 John Wiley & Sons Ltd.

2016 EvidenceUpdates

197. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION) (Abstract)

Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION) To compare the efficacy and safety of combination of vildagliptin and metformin therapy with metformin uptitration in Chinese patients with type 2 diabetes (T2DM) inadequately controlled with low-dose metformin.In this 24-week prospective (...) , randomized, multicentre, open-label study, patients with T2DM inadequately controlled with metformin ≤1000 mg daily were divided 1 : 1 : 1 : 1 into four prespecified subgroups based on age and body mass index (BMI). Patients in each subgroup were randomized 5 : 1 to receive either vildagliptin (50 mg twice daily) plus metformin [500 mg twice daily; vildagliptin and low-dose metformin (VLDM) group] or metformin uptitration [1000 mg twice daily; high-dose metformin (HDM) group]. The primary endpoint

2016 EvidenceUpdates Controlled trial quality: uncertain

198. Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study. Full Text available with Trip Pro

Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study.  To determine the association between use of sulphonylureas and risk of hypoglycaemia in relation to renal function and sulphonylurea metabolic group compared with use of metformin. Population based cohort study using routinely collected data from general practices in England. Clinical Practice Research Datalink (CPRD) database (...) for age, sex, lifestyle, comorbidity, and drug use. The risk of hypoglycaemia in current users of sulphonylureas only was significantly increased compared with current users of metformin only (adjusted hazard ratio 2.50, 95% confidence interval 2.23 to 2.82). The higher risk in current users of sulphonylureas only was further increased in patients with an estimated glomerular filtration rate of less than 30 mL/min/1.73 m(2) (4.96, 3.76 to 6.55). The risk of hypoglycaemia was also significantly higher

2016 BMJ

199. XIGDUO (dapagliflozin/metformin), antidiabetic - type-2 diabetes

XIGDUO (dapagliflozin/metformin), antidiabetic - type-2 diabetes XIGDUO SUMMARY CT14263

2016 Haute Autorite de sante

200. Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial Full Text available with Trip Pro

Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial To compare the efficacy and safety of liraglutide versus lixisenatide as add-on to metformin in patients with type 2 diabetes not achieving adequate glycemic control on metformin alone.In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin. Liraglutide (...) for lixisenatide; P = 0.23). The most common adverse events in both groups were gastrointestinal disorders. Greater increases in pulse, lipase, and amylase were observed with liraglutide. Hypoglycemic episodes were rare and similar between the two treatments.At the dose levels studied, liraglutide was more effective than lixisenatide as add-on to metformin in improving glycemic control. Body weight reductions were similar. Both treatments were well tolerated, with low risk of hypoglycemia and similar

2016 EvidenceUpdates Controlled trial quality: uncertain